Previous Close | 226.75 |
Open | 226.10 |
Bid | 0.00 x 0 |
Ask | 229.70 x 0 |
Day's Range | 226.10 - 230.05 |
52 Week Range | 222.75 - 293.55 |
Volume | |
Avg. Volume | 1,365,766 |
Market Cap | 184.558B |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | 16.05 |
EPS (TTM) | 14.31 |
Earnings Date | Feb 01, 2024 |
Forward Dividend & Yield | 9.60 (4.23%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | 364.36 |
Subscribe to Yahoo Finance Plus to view Fair Value for ROG.SW
The company is pitching the test as a way to improve the safety and availability of blood.
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malariaMalaria is a serious and potentially fatal parasitic infection most commonly transmitted by mosquitoes that can also be spread through blood transfusionRoche is dedicated to saving patients’ lives through diagnostic solutions that aid in the protection of the global blood supply from infectious diseases Basel, 26 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and